European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology · 2026
Nationwide strategies and outcomes of minimally invasive versus open combined liver ablation and resection for colorectal liver metastases.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Pilz da Cunha Gabriela, Balasupramaniam Ketharan, Kok Niels, Verhoef Cornelis, Gobardhan Paul D, Manusama Eric R, Dewulf Maxime J L, van der Leij Christiaan, Belt Eric J T, Mieog J Sven D, Burgmans Mark C, Leclercq Wouter K G, de Boer Marieke T, Ruiter Simeon J S, Patijn Gijs A, Vermaas Maarten, Hagendoorn Jeroen, Smits Maarten L J, Bosscha Koop, Oosterling Steven J, Torrenga Hans, Marsman Hendrik A, Consten Esther C J, Meijerink Martijn R, Swijnenburg Rutger-Jan, Dutch Hepato Biliary Audit Group Collaborators
Аннотация
BACKGROUND: Combined ablation and resection (CARe) reduces the need for major resection in patients with extensive colorectal liver metastases (CRLM). This study compares short-term outcomes of minimally invasive CARe (MI-CARe) vesus open CARe (O-CARe) for CRLM.
METHODS: This nationwide cohort study used data from the Dutch Hepato Biliary Audit (2018-2022) on adults undergoing single-session CARe for CRLM in the Netherlands. Perioperative outcomes up to 30 days postoperatively of MI-CARe and O-CARe were compared using Propensity Score Matching (PSM). Long-term oncological data were unavailable. A survey assessed variation in indications, techniques, and experience across hospitals.
RESULTS: A marked increase in MI-CARe was observed over the study period (16% in 2018 to 25% in 2022). Unmatched analysis revealed that O-CARe was more often applied in patients with more extensive disease, characterized by more CRLM, bilobar involvement and use of neoadjuvant chemotherapy. After PSM, MI-CARe was associated with reduced intraoperative blood loss (median 200 mL [IQR 100 - 500] vs 350 mL [IQR 150 - 800], p =< 0.001) and shorter hospital stays (median 3 days [IQR 2 - 5] vs 6 days [IQR 4 - 8], p < 0.001). No significant differences were observed in postoperative morbidity, readmission, or mortality. Considerable variation exists among hospitals in CARe practices.
CONCLUSION: MI-CARe appears feasible and safe for selected patients, and leads to shorter hospital stays and lower blood loss than O-CARe. Variation in practice and the lack of oncological data preclude conclusions about its superiority.
METHODS: This nationwide cohort study used data from the Dutch Hepato Biliary Audit (2018-2022) on adults undergoing single-session CARe for CRLM in the Netherlands. Perioperative outcomes up to 30 days postoperatively of MI-CARe and O-CARe were compared using Propensity Score Matching (PSM). Long-term oncological data were unavailable. A survey assessed variation in indications, techniques, and experience across hospitals.
RESULTS: A marked increase in MI-CARe was observed over the study period (16% in 2018 to 25% in 2022). Unmatched analysis revealed that O-CARe was more often applied in patients with more extensive disease, characterized by more CRLM, bilobar involvement and use of neoadjuvant chemotherapy. After PSM, MI-CARe was associated with reduced intraoperative blood loss (median 200 mL [IQR 100 - 500] vs 350 mL [IQR 150 - 800], p =< 0.001) and shorter hospital stays (median 3 days [IQR 2 - 5] vs 6 days [IQR 4 - 8], p < 0.001). No significant differences were observed in postoperative morbidity, readmission, or mortality. Considerable variation exists among hospitals in CARe practices.
CONCLUSION: MI-CARe appears feasible and safe for selected patients, and leads to shorter hospital stays and lower blood loss than O-CARe. Variation in practice and the lack of oncological data preclude conclusions about its superiority.